XXIV EFMC International Symposium on Medicinal Chemistry
Manchester, UK August 28
University of Dundee, Glasgow, United Kingdom
University of Ljubljana, Ljubljana, Slovenia
University of Antwerp, Antwerp, Belgium
Novartis, South San Francisco, United States
University of Lille, Lille, France
Instituto de Quimica Medic, CSIC, Madrid, Spain
H. Lundbeck, Valby, Denmark
University of Lisbon, Lisbon, Portugal
Consultant, Bognor Regis, United Kingdom
Bayer Pharma, Berlin, Germany
AstraZeneca, Cambridge, United Kingdom
University of Oxford, Los Angeles, United States
University of Dundee, Glasgow, United Kingdom
Cancer Research UK Manchester Institute, Manchester, United Kingdom
Redx Anti-infectives Ltd, Alderley Edge, United Kingdom
Newcastle University, Newcastle upon Tyne, United Kingdom
Convergence Pharmaceuticals, United Kingdom
CNRS-Universty of Montpellier I, Montpellier, France
Leipzig University, Leipzig, Germany
Actelion Pharmaceuticals Ltd, Basel, Switzerland
Stratified Medical, Deal, United Kingdom
Medicines for Malaria Venture (MMV), Geneva, Switzerland
National Hellenic Research Foundation, Athens, Greece
Johnson & Johnson R&D, San Diego, United States
Merck, Darmstadt, Germany
University of Cape Town, Cape Town, South Africa
Eli Lilly and Company, Indianapolis, Indiana, United States
University of Parma, Parma, Italy
University of Sussex, Brighton, United Kingdom
Sanofi, Mölndal, Sweden
Boehringer Ingelheim Pharma, Biberach, Germany
Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
Bar-Ilan University, Ramat-Gan, Israel
University of Ljubljana, Ljubljana, Slovenia
ALMIRALL, BARCELONA, Spain
Vertex Pharmaceuticals, San Diego, United States
UCB Pharma S.A., Braine-l'Alleud, Belgium
University of Leiden, Leiden, The Netherlands
Medical University of Lublin, Lublin, Poland
Latvian Institute of Organic Synthesis, Riga, Latvia
Uppsala University, Uppsala, Sweden
Oxford University, Oxford, United Kingdom
Fidelta Ltd, Zagreb, Croatia
AstraZeneca, Gothenburg, Sweden
Instituto de Quimica Medica-CSIC, Madrid, Spain
University of Vienna, Vienna, Austria
Janssen R&D, Belgium
Confo Therapeutics, Brussels, Belgium
IQAC-CSIC, Barcelona, Spain
Mercachem-Syncom, Nijmegen, The Netherlands
University of Sao Paulo, Sao Paulo, Brazil
Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
LEO Pharma, Ballerup, Denmark
F.Hoffmann - La Roche, BASEL, Switzerland
Peking University, Shenzhen, China
TES Pharma srl, Corciano, Italy
Faculty of Pharmacy, University of Porto, Porto, Portugal
Institute of Biomedical Chemistry, Moscow, Russia
Grünenthal, Germany
Astex Pharmaceuticals, Cambridge, United Kingdom
Merck Research Laboratories, Kriens, Switzerland
Max Planck Institute of Colloids and Interfaces, Berlin, Germany
Novo Nordisk, Cambridge, United States
University of Copenhagen, Copenhagen, Denmark
University of Tokyo, Tokyo, Japan
Imperial College London, London, United Kingdom
VU University Amsterdam, Oegstgeest, The Netherlands
University of Sydney, London, United Kingdom
Esteve Pharmaceuticals, Barcelona, Spain
University of Manchester, Manchester, United Kingdom
SCT & NovAliX, Nijmegen, The Netherlands
European Institute of Oncology, Milano, Italy
Novartis Institutes for Biomedical Research, Basel, Switzerland
Vinča Institute of Nuclear Sciences, Belgrade, Serbia
Amgen China, Shanghai, China